Kohlberg Kravis Roberts & Co’s Amedisys AMED Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-109,026	Closed	-$12.8M	–	56
2018 Q4	$12.8M	Sell	109,026 -2,309,278	-95%	-$272M	0.23%	30
2018 Q3	$302M	Hold	2,418,304	–	–	3.43%	9
2018 Q2	$207M	Sell	2,418,304 -2,418,304	-50%	-$178M	2.35%	8
2018 Q1	$292M	Hold	4,836,608	–	–	3.55%	6
2017 Q4	$255M	Hold	4,836,608	–	–	2.51%	6
2017 Q3	$271M	Hold	4,836,608	–	–	3.13%	8
2017 Q2	$304M	Hold	4,836,608	–	–	3.44%	6
2017 Q1	$247M	Hold	4,836,608	–	–	4.43%	5
2016 Q4	$206M	Hold	4,836,608	–	–	3.29%	7
2016 Q3	$229M	Hold	4,836,608	–	–	2.85%	7
2016 Q2	$244M	Hold	4,836,608	–	–	2.57%	7
2016 Q1	$234M	Hold	4,836,608	–	–	2.32%	6
2015 Q4	$190M	Hold	4,836,608	–	–	1.85%	8
2015 Q3	$184M	Hold	4,836,608	–	–	1.95%	7
2015 Q2	$192M	Hold	4,836,608	–	–	1.74%	9
2015 Q1	$130M	Hold	4,836,608	–	–	1.34%	8
2014 Q4	$142M	Hold	4,836,608	–	–	1.85%	6
2014 Q3	$97.6M	Hold	4,836,608	–	–	2.76%	8
2014 Q2	$81M	Hold	4,836,608	–	–	2.38%	11
2014 Q1	$72M	Hold	4,836,608	–	–	1.21%	11
2013 Q4	$70.8M	Buy	+4,836,608	New	+$77.9M	1.19%	10

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kohlberg Kravis Roberts & Co's AMED Position: Q1 2019 in Review

Kohlberg Kravis Roberts & Co sold out of Amedisys (AMED) in Q1 2019, closing a stake of 109,026 shares — an estimated $12.8M sold.

Kohlberg Kravis Roberts & Co first reported a position in AMED in Q4 2013 and held it in 21 quarters. The position peaked at $304M in Q2 2017. 317 funds tracked by Wall St. Rank hold AMED as of Q1 2019.

Kohlberg Kravis Roberts & Co reported no remaining Amedisys position as of Q1 2019 after selling out during the quarter.
Kohlberg Kravis Roberts & Co sold 109,026 Amedisys shares in Q1 2019, an estimated $12.8M.
Kohlberg Kravis Roberts & Co first reported a position in Amedisys in Q4 2013 and held it in 21 quarters.
Kohlberg Kravis Roberts & Co's Amedisys position peaked at $304M in Q2 2017.
317 funds tracked by Wall St. Rank held Amedisys as of Q1 2019.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q1 2019, filed 15 May 2019.